A new blood test may predict Alzheimer’s risk, but it isn’t ready for prime time. The test measures levels of a biomarker called p-tau217, which is associated with the buildup of sticky beta-amyloid plaques in the brain. According to a new study, cognitively healthy older adults with high levels of p-tau217 in their blood had an estimated 38% greater chance of developing early signs of dementia over five years.
How the Test Works
The test measures levels of phosphorylated tau 217, or p-tau217, in the blood. This biomarker is strongly associated with the buildup of beta-amyloid plaques in the brain, which can trigger inflammation and damage communication between neurons. The test is not recommended for cognitively healthy people, but specialists can use it in people with signs of mild cognitive impairment or more advanced dementia.
Researchers are hopeful that the p-tau217 test can one day function like tests that measure a person’s risk of developing diabetes or having a heart attack. However, the research is in its early stages and needs to be repeated in larger studies that include people from all walks of life with different levels of sickness.
Original reporting: KRDO (Colorado Springs metro) — read the source article.
